



ndd EasyOne Pro™ Single Breath DLCO ROI

EasyOne Pro is the first lung function instrument allowing single breath DLCO measurement outside of the lung function laboratory. ndd's unique ultrasound technology eliminates complex calibration and maintenance procedures as required in today's laboratory equipment. We are pleased to offer a device that allows physicians to provide their patients with prompt, accurate diagnosis and treatment. The overwhelming number of undiagnosed and untreated cases of lung disease emphasizes the need for better diagnostic tools. ndd Medical Technologies is committed to setting new standards in pulmonary function testing by offering innovative, easy to use products and excellent customer support.

Number of Tests per Week

Tests per Week	1 Year Revenue	5 Year Revenue
4	\$31,616	\$158,080
8	\$63,232	\$316,160
12	\$94,848	\$474,240

CPT Coding

Code*	Description	Average Reimbursement
94010	Spirometry	\$35
94060	Pre and Post Bronchodilator administration, Spirometry as in 94010, Bronchodilation responsiveness, Flow volume loop	\$60
94720	Single Breath Diffusion Carbon Monoxide Diffusion Capacity	\$52
94240	Residual Lung Capacity Functional residual capacity or residual volume: helium method.	\$40
Total Medicare Average:		\$152

*These codes are based on United States Medicare National Average

Enter these codes to find the reimbursement in your territory from the following website: https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp

Indications for DLCO Measurement

- Evaluation and follow-up diseases which involve lung parenchyma (e.g., those associated with dusts, drug reactions, or sarcoidosis)
- Evaluation and follow-up of emphysema
- Differentiating among chronic bronchitis, emphysema, and asthma
- Evaluation of pulmonary involvement in systemic disease
- Evaluation of cardiovascular diseases
- Prediction of arterial desaturation during exercise in some patients with lung disease
- Evaluation and quantification of impairment and disability associated with interstitial lung diseases and emphysema
- Evaluation of the pulmonary effects of chemotherapy agents or other drugs known to induce pulmonary dysfunction
- Evaluation of pulmonary hemorrhage

As an early indication of certain pulmonary infections that cause diffuse pneumocystis (e.g., pneumocystis pneumonia)

Common ICD-9 Codes

- **496**—Chronic airway obstruction
- **493.2**—Chronic obstructed asthma
- **491.21**—With acute exacerbation
- **518.81**—Acute respiratory failure
- **786.09**—Other respiratory